Gm Advisory Group, Inc. Bristol Myers Squibb CO Transaction History

Gm Advisory Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $5,096 - $5,659	-80 Reduced 2.33%	3,357 $214,000
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $225,845 - $256,159	3,437 New	3,437 $238,000
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $245,165 - $270,012	-3,376 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $122 - $147	-2 Reduced 0.06%	3,376 $247,000
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $24,640 - $26,833	-398 Reduced 10.54%	3,378 $226,000
Q1 2021 May 13, 2021	BUY	$59.34 - $66.74 $224,067 - $252,010	3,776 New	3,776 $238,000
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $220,220 - $249,550	-3,814 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$57.43 - $63.64 $126,346 - $140,008	-2,200 Reduced 36.58%	3,814 $230,000
Q2 2020 Aug 13, 2020	BUY	$54.82 - $64.09 $33,604 - $39,287	613 Added 11.35%	6,014 $354,000
Q1 2020 May 13, 2020	BUY	$46.4 - $67.43 $102,080 - $148,346	2,200 Added 68.73%	5,401 $301,000
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $157,521 - $205,472	3,201 New	3,201 $205,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Gm Advisory Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Gm Advisory Group, Inc. with notifications on news.